Well, here we are at the end of 2020 and Amgen stock is down 6% while the S&P500 is up 15%. So how is that R&D transformation going?
For 2020, the IBB biotechnology index is up 27%, whereas Amgen is down 5% missing the largest biotech rally since 2014. Sad, sad, sad. Transformation is a joke and Bradway needs to go.
Teze stumbled, but omecamtiv mecarbil failing after it cleared futility analysis was a sad disappointment. I knew something was up when senior management continued to universally comment "high risk, high reward" whenever omecamtiv mecarbil was mentioned during a conference call.
Yes, but you’re going first. Layoffs in early Q1. Need to take action to cut costs to drive the stock price back up.
Stock price does have something to do with spending 90% of our time on web calls, sending emails to our customer's junk folders, doing expense reconciliations, endless ATLAS exercises, or submitting to covid tests. The rest of the time you can get lectured about your conscious bias, donating to BLM and endorsing books in HR about White Mediocrity.